Iminosugar compounds with antiflavirus activity
An anti-viral compounds effective against viruses belonging to the Flaviviridae family, wherein the anti-viral compounds are 1,5-dideoxy-1,5-imino-D-glucitol derivative compounds having the general formula (I) wherein R 2 , R 3 , R 4 and R 5 are the same or different and are selected from the group consisting of hydrogen, acyl, benzyl, alkyl, aryl, sulfonyl, phosphonyl, silyl, R 6 is at least one of alkyl or branched alkyl, heteroalkyl or aryl, R 6 ′ is a bridging group selected from at least one of bicycle[2.2.1]heptyl, bicycle[3.2.1]octyl, oxa analogs, admonyl and cubyl, n′=2-10, n″=1-10, enantiomers and stereoisomers of said compounds and physiologically acceptable salts or solvates of said compounds, enantiomer or stereoisomer.
1. A 1,5-dideoxy-1,5-imino-D-glucitol derivative compound having the general formula (I)
wherein R 2 , R 3 , R 4 and R 5 are the same or different and are selected from the group consisting of hydrogen, acyl, benzyl, alkyl, aryl, sulfonyl, phosphonyl, silyl,
R 6 is at least one of alkyl or branched alkyl, heteroalkyl, hydrogen, or aryl,
R 6 ′ is hydrogen,
n′=2-10,
n″=4-6
or an enantiomers or stereoisomer of said compound and physiologically acceptable salts of said compound, enantiomer or stereoisomer.
2. The compound of claim 1 , wherein n′ is 4, 5, or 6.
3. The compound of claim 1 , wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is N-pentyl(1-hydroxycyclohexyl)-1,5-dideoxy-1,5-imino-D-glucitol and has the general formula (III):
4. The compound of claim 1 , wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is N-butyl(1-hydroxycyclohexyl)-1,5-dideoxy-1,5-imino-D-glucitol and has the general formula (IV):
5. The compound of claim 1 , wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is N-hexyl(1-hydroxycyclohexyl)-1,5-dideoxy-1,5-imino-D-glucitol and has the general formula (V):
6. An anti-viral composition comprising a 1,5-dideoxy-1,5-imino-D-glucitol derivative compound having the general formula (I)
wherein R 2 , R 3 , R 4 and R 5 are the same or different and are selected from the group consisting of hydrogen, acyl, benzyl, alkyl, aryl, sulfonyl, phosphonyl, silyl,
R 6 is at least one of alkyl or branched alkyl, heteroalkyl, hydrogen, or aryl,
R 6 ′ is hydrogen,
n′=2-10,
n″=4-6,
or an enantiomers or stereoisomer of said compound and physiologically acceptable salts of said compound, enantiomer or stereoisomer.
7. The anti-viral compound of claim 6 , wherein n′ is 4, 5, or 6.
8. A method for inhibiting production of a virus belonging to the Flaviviridae family comprising contacting a mammalian cell infected by said virus with an effective amount of an anti-viral composition comprising the anti-viral compound of claim 6 .
9. The method of claim 8 , wherein in the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound, R 7 is a C 4 -C 6 alkyl moiety.
10. The method of claim 8 , wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is N-pentyl(1-hydroxycyclohexyl)-1,5-dideoxy-1,5-imino-D-glucitol and has the general formula (III):
11. The method of claim 8 , wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is N-butyl(1-hydroxycyclohexyl)-1,5-dideoxy-1,5-imino-D-glucitol and has the general formula (IV):
12. The method of claim 8 , wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound is N-hexyl(1-hydroxycyclohexyl)-1,5-dideoxy-1,5-imino-D-glucitol and has the general formula (V):
13. The method of claim 8 , wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound, enantiomer, or stereoisomer, or physiologically acceptable salt of said compound, enantiomer, or stereoisomer is administered to a mammal.
14. The method of claim 8 , wherein the 1,5-dideoxy-1,5-imino-D-gucitol derivative compound, enantiomer, or stereoisomer, or physiologically acceptable salt of said compound, enantiomer, or stereoisomer is administered to a human.
15. The method of claim 8 , wherein the 1,5-dideoxy-1,5-imino-D-glucitol derivative compound, enantiomer, or stereoisomer, or physiologically acceptable salt of said compound, enantiomer, or stereoisomer is administered to said mammalian cell in vivo.
16. The method of claim 8 , wherein said virus is at least one of West Nile fever virus, dengue virus, bovine viral diarrhea virus, and hepatitis B virus.
17. The method of claim 11 , wherein said virus is a flavivirus.
18. The method of claim 17 , wherein the flavivirus is selected from the group consisting of yellow fever virus, Japanese encephalitis virus, Murray Valley encephalitis, Rocio virus, St. Louis encephalitis virus, tick-borne encephalitis virus, Louping ill virus, Powassan virus, Omsk hemorrhagic fever virus and Kyasanur forest disease virus.
19. The method of claim 17 , said virus is a pestivirus.
20. The method of claim 17 , said virus is at least one of bovine diarrhea virus or hepatitis C virus.